$9.80
0[0.00%]
Last update: 4:00PM Get Real Time Here
Astria Therapeutics
(NASDAQ:ATXS)Astria Therapeutics Stock (NASDAQ:ATXS), Analyst Ratings, Price Targets, Predictions
Astria Therapeutics Inc has a consensus price target of $21.6, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and Jefferies on April 23, 2024, March 26, 2024, and March 25, 2024. With an average price target of $21.67 between HC Wainwright & Co., Wedbush, and Jefferies, there's an implied 119.97% upside for Astria Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Jefferies
Oppenheimer
Evercore ISI Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Astria Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 62.44% | HC Wainwright & Co. | Joseph Pantginis | $18 → $16 | Maintains | Buy | Get Alert |
| 03/26/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 123.35% | Wedbush | Laura Chico | → $17 | Maintains | Outperform | Get Alert |
| 03/25/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 174.11% | Jefferies | Eun Yang | $22 → $27 | Maintains | Buy | Get Alert |
| 03/25/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | HC Wainwright & Co. | Joseph Pantginis | $18 → $18 | Maintains | Buy | Get Alert |
| 03/14/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 72.59% | Wedbush | Laura Chico | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 03/05/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | HC Wainwright & Co. | Joseph Pantginis | → $18 | Reiterates | Buy → Buy | Get Alert |
| 01/30/2024 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 72.59% | Wedbush | Laura Chico | → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 11/15/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 153.81% | Oppenheimer | Hartaj Singh | $30 → $25 | Maintains | Outperform | Get Alert |
| 10/13/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | Wedbush | Laura Chico | $25 → $18 | Maintains | Outperform | Get Alert |
| 10/12/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | HC Wainwright & Co. | Joseph Pantginis | $20 → $18 | Maintains | Buy | Get Alert |
| 08/08/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 153.81% | Wedbush | Laura Chico | $26 → $25 | Maintains | Outperform | Get Alert |
| 08/08/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 103.05% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 204.57% | Oppenheimer | Hartaj Singh | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 163.96% | Wedbush | Laura Chico | → $26 | Reiterates | → Outperform | Get Alert |
| 05/12/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 103.05% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 82.74% | Evercore ISI Group | Liisa Bayko | → $18 | Initiates | → Outperform | Get Alert |
| 02/24/2023 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 103.05% | HC Wainwright & Co. | Joseph Pantginis | → $20 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | ATXS | Buy Now | Astria Therapeutics | $9.85 | 103.05% | HC Wainwright & Co. | Joseph Pantginis | $13 → $20 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Astria Therapeutics (ATXS)?
The latest price target for Astria Therapeutics (NASDAQ: ATXS) was reported by HC Wainwright & Co. on April 23, 2024. The analyst firm set a price target for $16.00 expecting ATXS to rise to within 12 months (a possible 63.27% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
The latest analyst rating for Astria Therapeutics (NASDAQ: ATXS) was provided by HC Wainwright & Co., and Astria Therapeutics maintained their buy rating.
When was the last upgrade for Astria Therapeutics (ATXS)?
There is no last upgrade for Astria Therapeutics.
When was the last downgrade for Astria Therapeutics (ATXS)?
There is no last downgrade for Astria Therapeutics.
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $18.00 to $16.00. The current price Astria Therapeutics (ATXS) is trading at is $9.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.